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Reactive oxygen species (ROS) are the primary pathogenic molecules produced in viral
lung infections. We previously reported on the use of a recombinant human serum albu-
min (HSA)–thioredoxin 1 (Trx) fusion protein (HSA–Trx) for extending the half-life Trx, an
endogenous protein with anti-oxidant properties. As a result, it was possible to overcome
the unfavorable pharmacokinetic and short pharmacological properties of Trx. We hypoth-
esized that HSA–Trx would attenuate the enhanced ROS production of species such as
hydroxyl radicals by neutrophils during an influenza viral infection. The levels of 8-hydroxy-
2′-deoxyguanosine and 3-nitrotyrosine were used as indices of the anti-oxidant activity of
HSA–Trx. In addition, the cytoprotective effects of HSA–Trx were examined in PR8 (H1N1)
influenza virus-induced lung injured mice. The findings show that HSA–Trx reduced the
number of total cells, neutrophils, and total protein in BALF of influenza virus-induced
lung injured mice. The HSA–Trx treatment significantly decreased the level of 8-hydroxy-
2′-deoxyguanosine and 3-nitrotyrosine, but failed to inhibit inducible nitric oxide synthase
expression, in the lungs of the virus-infected mice. On the other hand, Tamiflu® treatment
also significantly suppressed the production of inflammatory cells and neutrophil infiltra-
tion, as well as the protein level in BALF and lung histopathological alterations caused by
the influenza virus. The suppressive effect of Tamiflu® was slightly stronger than that of
HSA–Trx. Interestingly, Tamiflu® significantly decreased virus proliferation, while HSA–Trx
had no effect.These results indicate that HSA–Trx may be of therapeutic value for the treat-
ment of various acute inflammatory disorders such as influenza-virus-induced pneumonia,
by inhibiting inflammatory-cell responses and suppressing the overproduction of NO in the
lung.
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INTRODUCTION
Influenza virus infections cause a broad array of illnesses, includ-
ing acute lung injuries (ALI), which are responsible for vital
morbidity and mortality both in children and adults (1). Although
most influenza A viruses cause a transitory localized debilitating
respiratory illness in human beings, more severe respiratory and
systemic complications that are sometimes fatal can arise, as evi-
denced by the pandemic influenza of 1918 caused by the H1N1
virus and the highly pathogenic avian H5N1 virus (2). In addition,
the novel swine-origin influenza virus H1N1 that spread globally
in 2009 was an attenuated strain, but children and patients with a
pre-existing disease developed more severe infections (3).
There are several, currently available antiviral therapeutic
agents, including neuraminidase inhibitors, oseltamivir (Tami-
ful®) and zanamivir (Relenza®) to combat seasonal and pandemic
influenza A virus outbreaks (4). These antiviral agents that prevent
the release of the influenza virus from already infected cells and
the transmission of the virus are clearly effective in the treatment
of such infections. However, emerging evidence suggests that cer-
tain strains of the influenza virus are developing resistance to these
antivirals, and sometimes cause severe ALI, requiring intensive care
and mechanical ventilation in clinical settings (5). Therefore, the
development of newer, more effective therapeutic approaches that
differ from traditional virus based strategies is of great importance.
Recent studies have suggested that oxidative stress plays an
important role in the pathogenesis and development of influenza-
induced ALI (6). At the time of an influenza infection, several
cells of the innate immune system, such as alveolar macrophages
and neutrophils release reactive oxygen species (ROS) and reactive
nitrogen species (RNOS), including as superoxide (O−2 ), hydroxyl
radical (·OH), nitric oxide (NO), and peroxynitrite (ONOO−)
in order to combat the invading virus. However, the resulting
overproduced ROS and RNOS not only exert a direct cytopathic
effect on viral replication in the infected cells but also induced the
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apoptotic cell death of non-infected cells. That ROS and RNOS
play critical roles as mediators of virus-induced lung damage
is supported studies in which exogenous anti-oxidants, such as
superoxide dismutase (SOD), catalase (anti-oxidative enzymes),
allopurinol (xanthine oxidase inhibitor), or N -monomethyl-l-
arginine (NO synthase inhibitor) decreased the extent of lung
damage and mortality in influenza-infected mice (7–9). In addi-
tion, the overexpression of extracellular SOD or heme oxygenase-1
was reported to suppress lung injury and inflammation, resulting
in an improved survival rate (10, 11).
Thioredoxin-1 (Trx) is a small redox-active protein (12 kDa)
that is ubiquitously present in the human body and is one of the
defense proteins that are induced in response to various oxida-
tive stress conditions (12). In addition to its potent anti-oxidative
effect, which is derived from dithiol-disulfide exchange in its active
site, Trx also has anti-inflammatory properties, due mainly to
its ability to inhibit neutrophil chemotaxis to inflammatory sites
(13). Because of its desirable anti-oxidative and anti-inflammatory
properties, Trx represents a new and potentially effective thera-
peutic agent for the treatment of influenza virus-induced ALI.
However, since Trx is eliminated extensively via glomerular fil-
tration, its plasma half-life is only about 1 h in mice and 2 h in
rats, which is extremely short in terms of producing a signifi-
cant therapeutic impact (13, 14). In order to obtain a satisfactory
therapeutic outcome, a sustainable therapeutic concentration of
Trx would be needed. To achieve this, a constant infusion or
frequent repeated administrations of Trx would be required. In
fact, Yashiro et al. reported that exogenous recombinant Trx was
effective in inhibiting influenza virus-induced lung damage, when
administered intraperitoneally 2 day intervals (15).
In an attempt to increase the blood retention time of Trx, we
recently produced a genetically engineered fusion protein com-
prises human serum albumin (HSA) and Trx (HSA–Trx) using a
Pichia expression system (16). The incentives for targeting albu-
min are that it constitutes the most abundant serum protein in
blood, and albumin has an extraordinary long half-life of 2–
3 weeks in human beings. In addition to having a molecular size
above the renal clearance threshold, the long half-lives are attrib-
uted to the efficient receptor-mediated recycling pathway involving
the neonatal Fc receptor (FcRn) (17). Actually, the plasma half-life
of the HSA–Trx fusion protein in normal mice was found to be
similar to that of HSA, which is 10 times longer than the plasma
half-life of Trx itself. Interestingly, HSA–Trx showed a higher dis-
tribution in the lungs than Trx (16). Therefore, a further attempt
will be made to investigate the clinical usefulness of HSA–Trx in
treating oxidative stress and inflammation related lung disorders.
The purpose of this study was to investigate the therapeu-
tic impact of HSA–Trx in the treatment of influenza-induced
ALI. Using an influenza-induced ALI mouse model, the results
showed that HSA–Trx could prevent this disease via its long acting
anti-oxidative and anti-chemotaxis effects.
MATERIALS AND METHODS
EXPERIMENTAL ANIMALS AND REAGENTS
Sea-ICR mice (5 weeks, male) were obtained from Kyudo Co.,
Ltd. (Saga, Japan). Blue Sepharose 6 Fast Flow, HiTrap Phenyl
HP column and PD-10 desalting column were obtained from GE
Healthcare (Tokyo, Japan). Chloral hydrate was obtained from
Sigma (Tokyo, Japan). Diff-Quick reagents were purchased from
Kokusai Shiyaku (Kobe, Japan). Coomassie Brilliant Blue solu-
tion and HistoVT One were obtained from Nacalai Tesque (Kyoto,
Japan). Interferon-γ (IFN-γ) ELISA kit was purchased from Biole-
gend (San Diego, CA, USA). Mayer’s hematoxylin, a 1% eosin
alcohol solution, mounting medium for histological examinations
(malinol) were from Muto Pure Chemicals (Tokyo, Japan). 4′,6-
Diamidino-2-phenylindole (DAPI) was obtained from Dojindo
(Kumamoto, Japan). All other chemicals were of the highest
analytical grades available.
PRODUCTION OF HSA–Trx FUSION PROTEIN
Human serum albumin, Trx, and the HSA–Trx fusion protein
were produced following previously reported methods (18, 19).
Transformed Pichia pastoris cells were incubated in 1250 ml of
BMGY liquid media [1% yeast extract, 2% pepton, 100 mM
potassium phosphate (pH 6.0), 1.34% yeast nitrogen base with
ammonium sulfate without amino acids, 4× 10−5% biotin, 1%
glycerol] (growth phase) for 2 days (OD600= 2), and was then
cultured in 800 ml of BMMY media that contained a protein
expression inducer as well as a carbon source, methanol [1% yeast
extract,2% pepton,100 mM potassium phosphate (pH 6.0),1.34%
yeast nitrogen base with ammonium sulfate without amino acids,
4× 10−5% biotin, 1% methanol] (protein induction phase) for
3 days at 30°C. Methanol was added at 12 h intervals to permit
the concentration of methanol to be maintained at 1% in order
to sustain the protein expression induction effect. Purification
of the fusion protein was initially carried out by chromatogra-
phy on a Blue Sepharose 6 Fast Flow column equilibrated with
200 mM sodium acetate buffer (pH 5.5) after dialysis against the
same buffer. Using AKTA prime, a 5 ml HiTrap Phenyl HP col-
umn for hydrophobic chromatography, the following conditions
were employed: Buffer A, 50 mM Tris-HCl/1.5 M ammonium sul-
fate, pH 7.0; Buffer B, 50 mM Tris-HCl, pH 7.0; Gradient, 0–100%
(Buffer B) 100 ml; Flow rate,3 ml/min. The fusion protein was ana-
lyzed by SDS-PAGE on a 10% polyacrylamide gel, with Coomassie
blue R250 staining. The purity of the fusion protein was estimated
to be in excess of 97%.
PRODUCTION OF INFLUENZA-INDUCED ALI MICE MODEL
Influenza virus A/Puerto Rico/8/34 (H1N1) was used through-
out the experiments. All animal experiments were conducted in
accordance with the guidelines of Center for Animal Resources
and Development, Kumamoto University for the care and use of
laboratory animals. All animal experiments were approved by the
experimental animal ethics committee at the Kumamoto Univer-
sity (B 26-058). Influenza-induced ALI model mice were produced
by intratracheal injection of influenza virus suspension diluted
with LB medium at a dose of 1.5× LD50 under anesthesia with
chloral hydrate (500 mg/kg) on day 0. Either Trx or HSA–Trx
was (but not both) administered intravenously (3.5 nmol pro-
tein in 200µl saline/mouse) via the mice tail vein at 4 and 6 days
after virus infection. Tamiful® was administrated intraperitoneally
(10 mg/kg/day, 2 times/day) for 4 days from 2 days after virus infec-
tion. The efficacy of therapeutic agents was evaluated with mice
sacrificed at 8 days after virus infection.
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ANALYSIS OF LUNG LAVAGE SAMPLES
The mice were anesthetized with diethyl ether, the chests were
opened, and blood was sampled for measurement of hydroper-
oxides (described below). BALF was collected by cannulating the
trachea and lavaging the lung with 1 ml of sterile PBS containing
50 U/ml heparin (two times). About 1.8 ml of BALF was rou-
tinely recovered from each animal. The BALF was centrifuged at
4,100× g for 5 min at 4°C to separate the cells in the BALF from
the liquid. Cells were suspended in 0.9% NaCl and the resulting
lysate was centrifuged again. From the recovered cells, the total cell
number was counted using a hemocytometer. Cells were stained
with Diff-Quick reagents, and the ratios of alveolar macrophages,
neutrophils, and lymphocytes to total cells were determined. More
than 200 cells were counted for each sample. The protein concen-
tration in BALF was measured with the Protein Assay Coomassie
Brilliant Blue solution with BSA as a standard. IFN-γ levels in
BALF were measured by ELISA, following the manufacturer’s
suggested protocol.
HISTOLOGICAL EXAMINATION OF LUNG TISSUE
For the histological analysis, the recovered lung tissues were fixed in
10% neutral-buffered formalin (Wako, Osaka, Japan), embedded
in paraffin (Sakura Finetek Japan, Tokyo, Japan) and sectioned at
4-µm thickness. The lung sections were subjected to hematoxylin
and eosin (HE) staining for morphologic analysis, and immuno-
histochemistry for inducible nitric oxide synthase (iNOS) (N-20)
(Santa Cruz Biotechnology, cat#: sc-651, Santa Cruz, CA, USA), 8-
hydroxy-2′-deoxygenase (8-OHdG) (15A3) (Santa Cruz Biotech-
nology, cat#: sc-66036, Santa Cruz, CA, USA), or 3-nitrotyrosine
(NO2-Tyr) (Millipore, cat#: AB5411, Billerica, MA, USA). For the
immunohistochemistry of iNOS, 8-OHdG, or NO2-Tyr, antigen
retrieval was first performed by means of HistoVT One. A solution
containing 50 mM Tris-HCl (pH 7.4) and 0.1% Tween-20 (T-TB)
was then used to solubilize the hepatic slices, followed by blocking
with Block Ace (Dainippon Pharmaceutical, Osaka, Japan) at 25°C
for 15 min. Next, reaction with the primary antibody was carried
out overnight at a temperature below 4°C. In addition, the pri-
mary antibodies against iNOS, 8-OHdG, or NO2-Tyr were diluted
(1:50) with 0.5% BSA in PBS before use and conjugated with
DAPI solution (10µg/ml). The hepatic slices were then washed
FIGURE 1 | Experimental protocol for the effective evaluation of
HSA–Trx,Trx, orTamiflu® on influenza-induced ALI model mice. Either
HSA–Trx or Trx was administrated intravenously (1.75 nmol/mouse) at 4 and
6 days after virus infection. Tamiflu® was administrated intraperitoneally
(10 mg/kg/day, 2 times/day) for a total of 4 days, starting 2 days after the
virus infection. The efficacy of therapeutic agents was evaluated with mice
sacrificed at 8 days after virus infection.
with T-TB, followed by reaction with the secondary antibody at
25°C for 1.5 h. For iNOS and NO2-Tyr immunostaining, Alexa
Fluor 488 goat anti-rabbit IgG (H+ L) (Invitrogen, cat#: A-11034,
Tokyo, Japan) and for 8-OHdG immunostaining, Alexa Fluor 555
goat anti-mouse IgG (H+ L) (Invitrogen, cat#: A-21424, Tokyo,
Japan) were diluted (1:200) with 0.5% BSA in PBS before use. After
the reaction, the slide was observed under a microscope (Keyence,
BZ-8000, Osaka, Japan). Image analyses of the extent and inten-
sity of iNOS, 8-OHdG and NO2-Tyr immunostaining were also
performed using the image J software.
MEASUREMENT OF PLASMA HYDROPEROXIDES
Plasma was prepared from recovered blood sample. The plasma
concentration of hydroperoxides (whole oxidant capacity of
plasma against N,N -diethylparaphenylene-diamine in acidic
buffer) was measured using the FREE carpe diem (Diacron
International, Grosseto, Italy) following the manufacturer’s rec-
ommended protocols. The measurement unit was CARR U. It
has been established that 1 CARR U corresponds to 0.08 mg/dl
hydrogen peroxide.
MEASUREMENT OF VIRUS LOAD IN LUNG TISSUE
The left lungs from influenza virus-infected mice were removed,
weighed, and homogenized in 1 ml of RPMI medium 1640. After
centrifugation at 100× g for 10 min at 4°C, the supernatant was
FIGURE 2 | Effect of HSA–Trx on the body weight (A) and survival (B) of
influenza-infected mice. HSA–Trx (3.5 nmol/mouse) was administrated
intravenously at 4 and 6 days after the virus infection. **P <0.01 or
*P < 0.05 as compared with saline (n=10).
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recovered. Virus titers were determined by a plaque assay on
Madin–Darby canine kidney (MDCK) cells. MDCK cells were
seeded on a 24 well culture plate and cultured until reach-
ing confluency. Cells were washed with PBS, and then 0.1-ml
amounts of each dilution were inoculated to cultured cell fol-
lowed by incubation for 1 h at 34°C. DMEM (0.5 ml) contain-
ing 100 U/ml penicillin, 100µg/ml streptomycin, and 0.5µg/ml
fungizone was added to each well and incubated at 37°C for
3 days in a humidified incubator with 5% CO2. Cytopathologi-
cal effect was calculated and 50% tissue culture infectious dose
(TCID50) was calculated using the formula developed by Reed
and Muench (20).
PREPARATION OF FLUORESCEIN ISOTHIOCIANATE-LABELED HSA–Trx
AND EVALUATION OF DISTRIBUTION TO BALF OF FITC-LABELED
HSA–Trx IN INFLUENZA-INFECTED MICE
Human serum albumin–Trx was labeled with fluorescein isothio-
cianate (FITC). HSA–Trx (4 mg/ml) and FITC (1 mg/ml) were dis-
solved in 0.15 M K2HPO4 (pH 9.5), followed by mixing for 4 h at
room temperature. The resulting solution was desalted by passage
through a PD-10 desalting column and eluent was concentrated by
Vivapore (Sartorius Stedim Biotech, A.S., France). FITC-labeled
HSA–Trx (3.5 nmol/mouse) was administrated intravenously to
normal mice or model mice at 4 or 6 days after virus infection.
At 2 h after its administration, the mice were anesthetized with
diethyl ether, the chests were opened, and blood was drained.
BALF was collected by cannulating the trachea and lavaging the
lung with 1 ml of sterile PBS containing 50 U/ml heparin. About
0.8 ml of BALF was routinely recovered from each animal. The
BALF was centrifuged at 4,100× g for 5 min at 4°C to separate the
cells in the BALF from the liquid. The BALF levels of FITC-labeled
HSA–Trx were quantified by using a spectral photometer (JASCO
Corporation, MODEL: PTL-3965, Tokyo, Japan).
STATISTICAL ANALYSIS
All data are expressed as the mean± SE. Significant differences
among each group were examined using a one-way of analysis
of variance (ANOVA) followed by Bonferroni multiple compar-
ison. A probability value of P < 0.05 was considered to indicate
statistical significance.
FIGURE 3 | Relative inhibitory effect of HSA–Trx orTrx on
influenza-infected mice. The same injected dose (3.5 nmol/mouse) of
HSA–Trx or HSA was administered intravenously at 4 and 6 days after the
virus infection. The numbers of (A) total cells and (B) neutrophils, or (C)
protein concentration in BALF were determined at 8 days after virus infection.
(D) Sections of pulmonary tissue were prepared at 8 days after virus infection,
and subjected to histopathological examination (HE staining). Magnifications:
×40 in (D); ×200 in (E). Each value represents the mean±SE (n=5).
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RESULTS AND DISCUSSION
EFFECT OF HSA–Trx ON BODY WEIGHT AND SURVIVAL OF
INFLUENZA-INFECTED MICE
Acute lung injury was induced in mice by a single intratracheal
administration of influenza virus at a dose of 1.5× LD50 (day
0). Since Yashiro et al. reported that the multiple administra-
tion of Trx (3.5 nmol/body) prevented influenza-induced ALI
(15), we adopted a dose of HSA–Trx equivalent to one Trx treat-
ment (3.5 nmol/body). In Figure S1 in Supplementary Material,
the time-dependent variation following the virus infection shows
that the infiltration of inflammatory cells, especially neutrophils
in BALF, lung edema, and injury was induced from day 4 to 6 after
the initial virus infection. In addition, as shown in Figure S1D in
Supplementary Material, the virus load after influenza infection
reached a peak at day 4, and then decreased. Therefore, HSA–Trx
was injected at days 4 and 6 after the virus infection (Figure 1).
As shown in Figure 2, the body weight of the saline treated
group mice decreased from day 6 after the virus infection, with
80% of them dead. On the other hand, HSA–Trx administra-
tion significantly suppressed the diminished body weight and
increased the survival rate in virus-infected mice. Finally, 70%
of the HSA–Trx treated mice were still alive at 14 days after the
virus infection.
RELATIVE INHIBITORY EFFECT OF HSA–Trx OR Trx ON
INFLUENZA-INFECTED MICE
We compared HSA–Trx vs. Trx for their protective effect at the
same administration schedule against influenza-induced ALI mice
(Figure 1). The influenza infection caused a significant induction
in the infiltration of inflammatory cells, especially neutrophils in
the BALF of infected mice on day 8 (Supporting Figure in Supple-
mentary Material). The number of total cells and neutrophils in
the BALF remained significantly lower in HSA–Trx treated mice
compared with saline or Trx treated mice (Figures 3A,B).
The extent of acute lung damage elicited by the influenza virus
infection was assessed based on the increase in total protein in
the BALF. We compared the levels of protein in the BALF from the
saline, HSA–Trx, or Trx treated mice. As shown in Figure 3C, HSA–
Trx significantly suppressed the elevation in the BALF protein that
was induced by the influenza virus. The Trx treatment failed to
FIGURE 4 | Effect of HSA–Trx on BALF IFN-γ and pulmonary iNOS
expression in influenza-infected mice. (A) IFN-γ levels in BALF were
determined, and (B) immunostaining of lung slice for iNOS/DAPI was
performed at 8 days after the influenza infection. (C) Image analysis of the
extent and intensity of iNOS/DAPI staining was performed. Each bar
represents the mean±SE [(A) n=5, (C) n=4]. NS; non-significant vs. saline.
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result in a significant reduction in the virus-induced elevation of
protein concentration in the BALF (Figure 3C).
Hematoxylin and eosin staining of lung sections indicated that
the virus-inoculated mice presented diffuse edema and inflam-
matory infiltration in the alveoli and interstitium of the lung,
hemorrhaging, and thickened airways on day 8 (Supporting Figure
in Supplementary Material). However, in lung sections from the
HSA–Trx administration group, the extent of damage was atten-
uated, compared with the saline treated group. Histopathological
findings for lung sections from the Trx administration group were
similar to that for the saline administration group (Figures 3D,E).
This tendency was similar to the previous findings for OVA or
BLM-induced lung injuries, in that HSA–Trx ameliorated these
lung injuries in an administration schedule in which Trx failed
to show any efficacy against these injuries (21, 22). Therefore, the
suppressive effect of HSA–Trx may be due to the extended reten-
tion of the fusion protein in the blood, compared to HSA via
FcRn.
FIGURE 5 | Effect of HSA–Trx on pulmonary and plasma
oxidative stress in influenza-infected mice. Immunostaining of
lung slice for (A) 8-OHdG/DAPI and (B) NO2-Tyr/DAPI was
performed at 8 days after the influenza infection. Image analysis of
the extent and intensity of (C) 8-OHdG/DAPI and (D) NO2-Tyr/DAPI
staining was performed. (E) Plasma hydroperoxide level was
determined at 8 days after influenza infection. Each bar represents
the mean±SE (n=4).
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EFFECT OF HSA–Trx ON BALF IFN-γ AND PULMONARY iNOS
EXPRESSION
A previous report indicated that a large amount of IFN-γ
was induced in BALF obtained from influenza virus infections,
and IFN-γ up-regulated the expression of iNOS in alveolar
macrophages, bronchial, and alveolar epithelial cells (9, 23). To
reveal the mechanism underlying the suppressive effect of HSA–
Trx on influenza-induced ALI, the levels of IFN-γ in BALF or the
expression of iNOS in lung tissue was confirmed by ELISA or
immunostaining, respectively. As shown in Figure 4, the admin-
istration of HSA–Trx failed to reduce the increased levels of
expressed IFN-γ and iNOS that were produced as the result of
a viral infection.
EFFECT OF HSA–Trx ON OXIDATIVE STRESS IN LUNG TISSUE
Previous reported findings suggest that ROS released from acti-
vated leukocytes, especially alveolar macrophages and neutrophils,
are associated with the development of influenza-induced ALI
(6). In fact, the genetic knockout of NADPH-oxidase in which
neutrophils are produced, resulted in the suppression of influenza-
induced ALI (24). In addition, NO released by iNOS reacts with
O−2 derived from activated leukocytes to produce peroxynitrite
(ONOO−) that has a strong injurious activity. ONOO− can nitrate
a wide range of biological targets, such as proteins and fatty acids
to produce NO2-Tyr adducts (25).
To evaluate the effect of HSA–Trx on the oxidative stress
induced by a virus infection, lung tissue was immunostained
FIGURE 6 | Relative inhibitory effect of HSA–Trx orTamiflu® on
influenza-infected mice. HSA–Trx (3.5 nmol/mouse) was administered
intravenously at 4 and 6 days after virus infection. Tamiflu® (5 mg/kg) was
administrated intraperitonealy every day at 2 times per day for a total of
4 days starting on 2 day after the influenza infection. The numbers of
(A) total cells and (B) neutrophils, or (C) protein concentration in BALF
were determined at 8 days after virus infection. (D) Sections of
pulmonary tissue were prepared at 8 days after virus infection, and
subjected to histopathological examination (HE staining). Magnifications:
×40 in (D); ×200 in (E). Each value represents the mean±SE (n=5).
*P <0.05 and **P <0.01 as compared with saline. #P <0.05 as
compared with HSA–Trx.
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for 8-OHdG and NO2-Tyr, an oxidized product of nucleic acids
and proteins, respectively, on day 8 after the influenza infection.
Additionally, to determine the levels of hydroperoxide in plasma,
dROMs tests were performed. As shown in Figure 5, the expression
of 8-OHdG and NO2-Tyr in lung tissue and plasma hydroperox-
ides levels were increased in influenza-infected mice compared
to normal mice, while HSA–Trx clearly suppressed the levels of
these oxidative stress markers. Our previous report suggested that
HSA–Trx has direct scavenging activities against (O−2 ) derived
from activated neutrophils and that this effect is concentration
dependent (22). Therefore, the inhibitory effect of oxidized prod-
ucts that accumulated was thought to involve the same mechanism
as proposed in a previous report. Furthermore, Trx has anti-
chemotaxis properties for neutrophils by inhibiting the activation
of p38 mitogen-activated protein kinase, the downregulation of
L-selectin (CD62L) and adhesion to endothelial cells (13). In
fact, as shown in Figure 3B, HSA–Trx significantly lowered the
number of neutrophils in the BALF of influenza-infected mice.
Taken together, the mechanism underlying the improving effect
of HSA–Trx on influenza-induced ALI could be not only attrib-
uted exclusively to an anti-oxidative effect but also anti-chemotaxis
appears to be involved.
RELATIVE INHIBITORY EFFECT OF HSA–Trx OR TAMIFLU® ON
INFLUENZA-INFECTED MICE
For future clinical applications, the inhibitory effect of HSA–Trx
against influenza-induced ALI was examined. A previous study
demonstrated that the intraperitoneal administration of Tamiflu®
(5 mg/kg) daily at two times per day showed a protective effect
for influenza-induced ALI (26). Hence, the inhibitory effect of
HSA–Trx (3.5 nmol/mouse, i.v.) at 4 and 6 days against influenza-
induced ALI was compared with that of Tamiflu® (5 mg/kg), which
was administered every day at 2 times per day for 4 days from
2 day after the influenza infection (Figure 1). The evaluation
items were the same as Figure 3. As shown in Figure 6, Tami-
flu® also significantly suppressed the derivation of inflammation
cells and neutrophils infiltration, protein elevation in BALF and
lung histopathological alteration caused by the influenza virus.
The suppressive effect of Tamiflu® treatment group was slightly
stronger than that of HSA–Trx.
EFFECT OF HSA–Trx OR TAMIFLU® ON VIRAL TITERS
To validate that HSA–Trx treatment did not inhibit viral replica-
tion, we performed a plaque-forming assay in MDCK cells using
the lung supernatant recovered from mice at day 4 or 6 after the
virus infection. As shown in Figure 7, although the Tamiflu®
treatment markedly inhibited virus proliferation, no significant
difference between the lung viral titers in the Saline and HSA–
Trx administration mice was found. These results indicate that
HSA–Trx, unlike a Tamiflu®, treatment ameliorates the acute lung
damage induced by the virus infection without affecting viral
propagation in the lungs of these mice.
BALF DISTRIBUTION OF FITC-LABELED HSA–Trx IN
INFLUENZA-INFECTED MICE
The concentration of albumin in alveolar fluid is usually much
lower than that in the blood, whereas the concentration can
FIGURE 7 | Effect of HSA–Trx orTamiflu® on pulmonary virus
replication in influenza-infected mice. HSA–Trx (3.5 nmol/mouse) was
administered intravenously at 4 and 6 days after the virus infection. Tamiflu®
(5 mg/kg) was administrated intraperitonealy every day at 2 times per day
for a total of 4 days starting on 2 day after the influenza infection. The virus
titles in lung tissue were determined at 4 and 6 days after the virus
injection. Each value represents the mean±SE (n=5).
increase to 75–95% of the plasma level in the case of a lung injury
due to vascular hyperpermeability caused by a marked elevation in
the surfactant’s surface tension (27). In fact, the albumin concen-
tration in BALF is used as a bio-marker of lung injuries in clinical
settings. Thus, it would be predicted that the BALF distribution of
exogenous HSA–Trx in influenza-infected mice would be higher
than that in influenza-non-infected mice. Hence, FITC-labeled
HSA–Trx was prepared, and the distribution to BALF at 2 h after
its administration in control mice (Day 0) or model mice on day
4 (Day 4) or 6 (Day 6) after the virus infection was evaluated. As
shown in Figure 8, the BALF distribution of FITC-labeled HSA–
Trx at Day 6 was approximately 4 times higher than that at Day 0.
This result suggests that the distribution of HSA–Trx to the site of
the lesion, the interstitium in influenza-infected patients may be
higher than that in healthy subjects.
CONCLUSION
We evaluated the therapeutic effects of HSA–Trx, a long-lasting
anti-oxidant and anti-inflammatory modulator that acts via the
efficient receptor-mediated recycling pathway involving FcRn,
on influenza-induced ALI model mice, and reached four major
findings; (1) The post-administration of HSA–Trx suppressed
influenza-induced ALI, (2) The mechanism by which HSA–Trx
inhibited influenza-induced ALI can be attributed to a combi-
nation of anti-oxidative and anti-chemotaxis effects, (3) Unlike
Tamiflu® the HSA–Trx treatment ameliorated acute lung damage
induced by the virus infection without affecting viral propagation
in the lung of these mice, (4) The distribution of HSA–Trx to the
lesion site, namely the interstitium in influenza-infected patients
may be higher than that in healthy subjects. Thus, we conclude
that HSA–Trx has considerable potential for use as a therapeutic
agent for the treatment of various acute inflammatory disorders
such as influenza-virus-induced pneumonia.
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FIGURE 8 | BALF distribution of FITC-labeled HSA–Trx in
influenza-infected mice. BALF levels of FITC-labeled HSA–Trx after
intravenous administration into the tail vein of normal (Day 0) or
influenza-infected (Day 4 or 6) mice were determined using fluorescence
spectroscopy. Each point represents the mean±SE (n=4). **P <0.01 vs.
Day 0.
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